Last reviewed · How we verify
Chinese patent medicine
Chinese patent medicine is a Small molecule drug developed by Tianjin University of Traditional Chinese Medicine. It is currently in Phase 3 development.
A traditional Chinese patent medicine formulation that modulates multiple biological pathways to address disease through herbal and mineral constituents.
At a glance
| Generic name | Chinese patent medicine |
|---|---|
| Sponsor | Tianjin University of Traditional Chinese Medicine |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Chinese patent medicines typically contain combinations of herbs, minerals, and animal-derived ingredients that work synergistically according to traditional Chinese medicine theory. Without specification of the exact formulation, the mechanism likely involves anti-inflammatory, immunomodulatory, or qi/blood-tonifying effects. The specific molecular targets and pathways depend on the individual herbal components and their active compounds.
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults (PHASE1)
- China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD (PHASE4)
- Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
- Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years (EARLY_PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults (PHASE1)
- Evaluation of the Food Effecton the Pharmacokinetics of FWD1802 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chinese patent medicine CI brief — competitive landscape report
- Chinese patent medicine updates RSS · CI watch RSS
- Tianjin University of Traditional Chinese Medicine portfolio CI